Novo Nordisk trial failure triggers GLUE premarket plunge
Novo Nordisk ziltivekimab Phase 3 CV trial failure triggers 39% GLUE premarket plunge
- NVO announced ZEUS trial miss: ziltivekimab (IL-6 inhibitor) lowered hsCRP/IL-6 but showed no MACE reduction (HR 0.99 vs placebo) in ASCVD/CKD patients with inflammation.
- Higher rates of serious infections also reported in the trial readout.
- GLUE's lead MRT-8102 (NEK7 molecular glue degrader) targets NLRP3 inflammasome upstream of IL-1/IL-6 pathway; recent GFORCE-1 interim data showed strong CRP reductions in elevated CVD risk patients.
- Market views NVO miss as negative read-through for inflammation-targeting approaches in cardiovascular disease, directly pressuring GLUE and peer BIOA (down ~50%).
- No Monte Rosa-specific news; Q2 earnings not due until early August; prior updates highlighted planned Phase 2 trials in CVD, gout, HS for MRT-8102.
- Sympathetic sell-off in premarket on July 31, 2026, erased much of recent gains as traders de-risk inflammation/CVD biotech plays.
- Analysts previously highlighted MRT-8102's potential in CVD based on CRP biomarker data; NVO results question clinical translation to outcomes.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.